Fig. 5
From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Immunological results of the AD-HPV16/18/58 mE6E7 adenovirus vaccine anti-tumor. A The serum antibody results of each group of mice in the HPV16 (TC-1 cell) group A: Mouse serum antibody results 1 week after the last injection, B: Mouse serum antibody results 2 weeks after the last injection. B The serum antibody results of each group of mice in the HPV18 (U14/LV-HPV18 E6E7 cell) group A: Mouse serum antibody results 1 week after the last injection, B: Mouse serum antibody results 2 weeks after the last injection. C The serum antibody results of each group of mice in the HPV58 (U14/LV-HPV58 E6E7 cell) group A: Mouse serum antibody results 1 week after the last injection, B: Mouse serum antibody results 2 weeks after the last injection. D The number of ELISPOT spots of IFN-γ in each group of HPV16 (TC-1 cell) mice. 168.33 ± 8.963 spots for the vaccine group, 8.00 ± 4.359 spots for the AD-NC group and 7.67 ± 2.517 spots for the PBS group were significant (P < 0.05). E The number of ELISPOT spots of IFN-γ in each group of HPV18 (U14/LV-HPV18 E6E7 cells) mice. 204.67 ± 11.676 spots for the vaccine group, 9.33 ± 1.528 spots for the AD-NC group and 6.33 ± 2.062 spots for the PBS group were significant (P < 0.05). F The number of ELISPOT spots of IFN-γ in each group of HPV58 (U14/LV-HPV58 E6E7 cells) mice. 234.00 ± 29.614 spots for the vaccine group, 8.67 ± 4.041 spots for the AD-NC group and 8.67 ± 2.517 spots for the PBS group were significant (P < 0.05). G Changes in T lymphocyte subsets in each group of mice in the HPV16 (TC-1 cell) group. H Changes in T lymphocyte subsets in each group of mice in the HPV18 (U14/LV-HPV18 E6E7 cells) group. I Changes in T lymphocyte subsets in each group of mice in the HPV58 (U14/LV-HPV58 E6E7 cell) group